Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study.
about
A Randomized Controlled Trial on the Effect of Tapentadol and Morphine on Conditioned Pain Modulation in Healthy VolunteersTapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.Combining opioid and adrenergic mechanisms for chronic pain.Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain.Patient considerations in the use of tapentadol for moderate to severe pain.Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painAnxiety and depression in patients with osteoarthritis: impact and management challenges.Tapentadol extended release for chronic pain patients.Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.Unique pharmacology of tapentadol for treating acute and chronic pain.Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.Assessment and manifestation of central sensitisation across different chronic pain conditions.Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research.Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.
P2860
Q28548331-F954E198-6D3A-4AC0-B831-B8D905B4225BQ31128284-D932C807-E078-4B11-8B89-36111FA030B2Q33938745-410D0349-38B2-43D4-9691-141F61CF50FFQ34434307-E996A02D-ED72-4B49-A284-A5025E9698E6Q35752535-7EBA3C09-80B4-4C41-8F71-A526F02F8839Q36991981-86595B7A-D953-428E-A1B1-5D7363F94346Q37115472-8D04D391-21E5-4015-BAB5-684F606408EAQ37398265-B193BF05-D76E-4EF8-9E18-6C20C8939A60Q38074832-793DB7B6-06C1-480C-993F-B534BF3957FFQ38767585-AE77673E-5C7E-4F84-BD71-FA4EB46DE794Q38980690-F29A910F-A53A-4FAB-88C6-6DCF3AF36C33Q39155270-24D6050E-0677-4385-A91B-5CE459763EAAQ47234803-92DC28CC-8075-4E7F-87C1-63906FF7AEFFQ50035203-37D31EF4-C426-407B-B955-4546F84C3C89Q52603231-C06D5A77-2022-4630-875C-1F457ED6EDA4
P2860
Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@ast
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
type
label
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@ast
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
prefLabel
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@ast
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
P2093
P2860
P356
P1476
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
P2093
Ilona Steigerwald
Jaime Calvo-Alén
Jean-Charles Balblanc
Jolanta Kujawa
Matthias Müller
P2860
P304
P356
10.2147/JPR.S30540
P577
2012-06-15T00:00:00Z